Salamanca

• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa … Ended recruitment
  2024-518304-53-00 5 2022-02-02 Relapsed or Refractory Multiple Myeloma (RRMM)
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended recruitment
  2023-506867-33-01 4 2022-01-25 Chronic Hepatitis B
• Study to evaluate the effects of CLR 131 in patients with B-Cell malignancies (CLOVER-1) and expansion study to evaluate the effects of CLR … Ended recruitment
  2023-508671-37-00 4 2021-12-02 Waldenstrom Macroglobulinemia
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, … Ended recruitment
  2024-517006-28-00 9 2021-11-23 Multiple myeloma
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti … Ended recruitment
  2024-516039-28-00 6 2021-09-28 Spontaneous Coronary Artery Dissection.
• A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim … Ended recruitment
  2023-508690-92-00 11 2021-09-20 IgA Nephropathy
• A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects … Ended recruitment
  2023-506094-35-00 3 2021-09-17 Newly diagnosed aggressive B-cell lymphoma (a-BCL)
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len … Ended recruitment
  2023-505850-16-00 5 2021-08-05 Multiple Myeloma
• DALY 2-EU Ended recruitment
  2023-506270-13-00 4 2021-07-27 Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
• Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease. Ended recruitment
  2024-512978-99-00 4 2021-07-19 Chronic graft versus host disease (cGVHD)
• Study of BGB-11417 in Patients with Mature B Cell Malignancies Ended recruitment
  2024-515592-35-00 1 2021-06-14 Mature B Cell Malignancies
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi … Ended recruitment
  2023-509635-89-00 9 2021-06-01 DIPSS-Intermediate or High Risk Myelofibrosis
• Phase III, multicentre, randomized, open clinical trial comparing treatment with allogenic mesenchymal cells against autologous mesenchymal … Ended recruitment
  2024-514545-11-00 5 2021-05-26 Knee osteoarthritis
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo … Ended recruitment
  2023-506526-37-00 5 2021-03-17 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended recruitment
  2023-507890-17-00 5 2021-02-22 Anemia associated with myeloproliferative neoplasm (MPN)-associated my
• A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis. Ended recruitment
  2022-503072-84-00 5 2021-02-13 stage IIIa cardiac AL amyloidosis
• A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended recruitment
  2022-503073-11-00 5 2021-02-13 Stage IIIb cardiac AL amyloidosis

Showing 289–312 of 470 trials